RSPI Projected Dividend Yield

Com Par $0.001/RespireRx Pharmaceuticals Inc ( OTCBB : RSPI )

RespireRx Pharmaceuticals is developing treatment options including obstructive sleep apnea, attention deficit hyperactivity disorder and recovery from spinal cord injury, as well as certain neurological orphan diseases such as Fragile X Syndrome. Co. is also developing a pipeline of drug products based on its patent portfolios across two drug platforms: cannabinoids, which include dronabinol; and neuromodulators, which include ampakines, proprietary compounds that positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate-type glutamate receptors to promote neuronal function and positive allosteric modulators of the gamma-amino-butyric acid type A receptors.

20 YEAR PERFORMANCE RESULTS